Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Thorax

• Publication date

  2016-01-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thoraxjnl-2015-207630PMID 26819354
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use.

  2015cited by this paper
• Chronic disease co-morbidity of asthma and unscheduled asthma care among adults: results of the national telephone health interview survey German Health Update (GEDA) 2009 and 2010

  2014cited by this paper
• What do we know about the safety of corticosteroids in rheumatoid arthritis?

  2013cited by this paper
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

  2013cited by this paper
• Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care

  2013cited by this paper
• Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.

  2013cited by this paper
• Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German national health telephone interview survey (GEDA) 2010

  2013cited by this paper
• Oral Corticosteroid Use Increases the Risk of Glucocorticoid-related Adverse Events in Asthmatics

  2012cited by this paper
• Comorbidities in an asthma population 8–29 years old: a study from the Norwegian Prescription Database

  2012cited by this paper
• Diseases Concomitant With Asthma in Middle-Aged and Elderly Subjects in Korea: A Population-Based Study

  2012cited by this paper
• Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review.

  2011cited by this paper
• Burden of comorbidity in individuals with asthma

  2010cited by this paper
• A comprehensive review of the adverse effects of systemic corticosteroids.

  2010cited by this paper
• Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry

  2010cited by this paper
• The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use.

  2009cited by this paper
• The Added Burden of Comorbidity in Patients with Asthma

  2009cited by this paper
• British Guideline on the Management of Asthma

  2008cited by this paper
• Corticosteroid-Induced Adverse Events in Adults

  2007cited by this paper
• Corticosteroid‐induced clinical adverse events: frequency, risk factors and patient’s opinion

  2007cited by this paper
• Coexistent chronic conditions and asthma quality of life: a population-based study.

  2006cited by this paper
• Psychological factors and asthma quality of life: a population based study

  2004cited by this paper
• Adverse effects of oral corticosteroids in relation to dose in patients with lung disease

  2001cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION

  1996cited by this paper
• Prevalence of adverse effects in corticosteroid dependent asthmatics.

  1988cited by this paper
• Complications of long-term steroid therapy for asthma.

  1972cited by this paper
• Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital.

  1968cited by this paper
• Long-term Steroid Therapy in Chronic Intractable Asthma

  1962cited by this paper
• Treatment of Chronic Asthma with Prednisolone and the Newer Steroids

  1961cited by this paper

• Beyond the Usual Suspects: Unmasking Low-T2 Asthma in Children

  2026cites this paper
• Pharmacological interactions between asthma and T2DM therapies: clinical and metabolic implications.

  2026cites this paper
• Association between neighborhood deprivation and type 2 diabetes risks among asthma patients: a nationwide population-based cohort study

  2025cites this paper
• Impact of demographics on mepolizumab effectiveness in severe asthma: One-year REALITI-A subanalysis (12/12 words).

  2025cites this paper
• Diabetes-inducing effects of bronchial asthma

  2025cites this paper
• Osteoporosis in Severe Asthmatic Patients: Data from the Severe Asthma Network in Italy (SANI) Registry

  2025cites this paper
• Impact of clinical remission on quality of life in severe eosinophilic asthma treated with mepolizumab.

  2025cites this paper
• Corticosteroid insensitivity in asthma associated with obstructive sleep apnoea: Role of oxidative stress and histone acetylation

  2025cites this paper
• Health system characteristics and evidence-based asthma care

  2025cites this paper
• International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

  2025cites this paper
• Economic impact of steroid-induced comorbidities in severe asthma: a SHARP CRC simulation

  2025influential citation
• Assessment of an oral corticosteroid withdrawal pathway for severe asthma patients receiving biologic therapies.

  2025cites this paper
• Predicting Risk of Morbidities Associated with Oral Corticosteroid Prescription for Asthma

  2025cites this paper
• The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma

  2025influential citation
• Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities

  2025cites this paper
• Ensuring patient safety: a closer look at glucocorticoid therapy in COPD and asthma

  2025cites this paper
• Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach

  2025cites this paper
• Costs of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry

  2025cites this paper
• Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics.

  2025cites this paper
• Prevalence of Three Prominent Corticosteroid Side Effects in a Large Asthma Population by Age, Sex and ICD-10 Asthma Severity with Recommendations for Screening.

  2025cites this paper
• Use of oral corticosteroids in patients with asthma: how far is clinical practice from the guidelines? Results from surveys of patients and doctors

  2025cites this paper
• Diagnosis and treatment options for T2-low asthma.

  2025cites this paper
• Hidden burden: discrepancies between patient-reported and clinically documented severe asthma exacerbations.

  2025cites this paper
• Financial burden of productivity loss in severe asthma and impact of biologic therapy.

  2025cites this paper
• Disease Trajectory and Treatment Escalation in Asthma: A Retrospective Analysis of Data From the Optimum Patient Care Research Database (OPCRD).

  2025cites this paper
• Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial.

  2024cites this paper
• Promoting Prevention and Targeting Remission of Asthma A EUFOREA Consensus Statement on Raising the Bar in Asthma Care.

  2024cites this paper
• Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme

  2024cites this paper
• Maintenance oral steroids are not required in severe asthma

  2024cites this paper
• Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK

  2024cites this paper
• Natural killer cells in the lung: novel insight and future challenge in the airway diseases

  2024cites this paper
• Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients

  2024cites this paper
• Tezepelumab: a promising therapy for severe uncontrolled asthma

  2024cites this paper
• Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions

  2024cites this paper
• Barriers to clinical remission in severe asthma

  2024cites this paper
• The global burden of cardiovascular disease attributable to diet low in fiber among people aged 60 years and older, 1990–2019: an age–period–cohort analysis of the global burden of disease study

  2024cites this paper
• Change is in the air: key questions on the ‘Treatable Traits’ model for chronic airway diseases in primary care

  2024cites this paper
• [Effectiveness and safety of biological therapy in patients with severe asthma in a real clinical practice].

  2024cites this paper
• Epidemiology of patients with severe asthma in Japan: a nationwide descriptive study

  2024cites this paper
• Introducing the concept of loss of corticosteroid credit in asthma

  2024cites this paper
• Impact of comorbidities on EQ-5D quality-of-life index in severe asthma

  2024cites this paper
• Association of Obesity and Severe Asthma in Adults

  2024cites this paper
• Eosinophils and T2 inflammation in severe asthma

  2024cites this paper
• Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study

  2024cites this paper
• Next-Generation Therapeutic Approaches for Uncontrolled Asthma: Insights Into the Heterogeneity of Non-Type 2 Inflammation

  2024cites this paper
• Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes

  2024cites this paper
• Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases

  2024cites this paper
• Amygdalar involvement in respiratory dysfunction

  2024cites this paper
• Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR

  2024cites this paper
• Assessment of obstructive airway disease in the multicenter SWORD survey India

  2024cites this paper
• Sleep Deficiency, Sleep Apnea, and Chronic Lung Disease.

  2024cites this paper
• Characterization of Obesity in Severe Asthma in the German Asthma Net.

  2023cites this paper
• Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

  2023cites this paper
• Impact of initiatinG bioLogics In patients with severe asThma on long-Term OCS or frEquent Rescue steroids (GLITTER): data from the International Severe Asthma Registry.

  2023cites this paper
• Biologics for severe asthma—Which, when and why?

  2023cites this paper
• Usefulness of post-operative endoscopic score for optimal treatment selection in recurrent eosinophilic chronic rhinosinusitis

  2023cites this paper
• Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps.

  2023cites this paper
• Tingli Dazao Xiefei Decoction ameliorates asthma in vivo and in vitro from lung to intestine by modifying NO-CO metabolic disorder mediated inflammation, immune imbalance, cellular barrier damage, oxidative stress and intestinal bacterial disorders.

  2023cites this paper
• Asthma and increased risk of myocardial infarction and mortality among hypertensive Korean patients

  2023cites this paper
• A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma

  2023cites this paper
• Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

  2023cites this paper
• Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose

  2023cites this paper
• Asthma registries: Tedious paperwork or a versatile tool for the generation of knowledge—Insights from the Australasian Severe Asthma Registry (ASAR)

  2023cites this paper
• German Asthma Net – Was haben wir bisher gelernt?

  2023cites this paper
• Association of rest-activity circadian rhythm with chronic respiratory diseases, a cross-section survey from NHANES 2011-2014.

  2023cites this paper
• Design of Multitarget Inhibitors as Tracheal Smooth Muscle Relaxants.

  2023cites this paper
• One-day systemic corticosteroid administration for asthma and future “short bursts” risk in real clinical practice

  2023cites this paper
• Patient characteristics and eligibility for biologics in severe asthma: Results from the Greek cohort of the RECOGNISE "real world" study.

  2023cites this paper
• A randomised trial of a T2-composite-biomarker strategy adjusting corticosteroidtreatment in severe asthma, a post- hoc analysis by sex.

  2023cites this paper
• Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option

  2023cites this paper
• Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics

  2023cites this paper
• Strong and graded associations between level of asthma severity and all-cause hospital care use and costs in the UK

  2023cites this paper
• Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care

  2023cites this paper
• Inhaled Corticosteroid Exposure and Risk of Cataract in Patients with Asthma and COPD: A Systematic Review and Meta-Analysis

  2023cites this paper
• Transforming Care in Asthma and Chronic Obstructive Pulmonary Disease: An Expert View

  2023cites this paper
• Defining trajectory in severe asthma: can it be changed?

  2023cites this paper
• Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab

  2023cites this paper
• Oral Corticosteroids for Patients with Eosinophilic Diseases: An Expert Panel View on Use, Overuse, and Strategies to Reduce Use

  2023cites this paper
• Severe Asthma Patients: Can We Really Wean Them off of Oral Corticosteroids

  2023cites this paper
• Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry.

  2023cites this paper
• Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club

  2022cites this paper
• Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT

  2022cites this paper
• Long-term effect of asthma on the development of obesity among adults: an international cohort study, ECRHS

  2022cites this paper
• Exacerbation Profile and Risk Factors in a T2-Low Severe Asthma Population.

  2022cites this paper
• Characteristics, phenotypes, mechanisms and management of severe asthma

  2022cites this paper
• Sleep Deficiency, Sleep Apnea, and Chronic Lung Disease.

  2022cites this paper
• Overuse of oral corticosteroids in asthma is often underdiagnosed and inadequately addressed.

  2022cites this paper
• Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD.

  2022cites this paper
• Association of corticosteroid use and attention deficit/hyperactivity disorder in asthmatic children varies by age

  2022cites this paper
• Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

  2022cites this paper
• Recent advances in the immunopathogenesis of severe asthma.

  2022cites this paper
• ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

  2022cites this paper
• Unmet Need for Oral Corticosteroids Use and Exacerbations of Asthma in Primary Care in Taiwan

  2022cites this paper
• Comorbidities modify the phenotype but not the treatment effectiveness to mepolizumab in severe eosinophilic asthma.

  2022cites this paper
• Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma

  2022cites this paper
• Real-world effectiveness of benralizumab: results from the ZEPHYR 1 Study.

  2022cites this paper
• Current unmet needs and potential solutions to uncontrolled asthma

  2022cites this paper
• Roles of real-world evidence in severe asthma treatment: challenges and opportunities

  2022cites this paper
• Frailty and muscle weakness in elderly patients with asthma and their association with cumulative lifetime oral corticosteroid exposure.

  2022cites this paper
• Characteristics of Oral Corticosteroid Users Among Persons with Asthma on GINA Step 3 Therapy and Above: A Cross-Sectional Study in Portuguese Community Pharmacies

  2022influential citation